Market research
MTEM Molecular Templates Inc
OTCMKTS USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 658
- P/E ratio
- Not available
- Analyst target
- 18
- Dividend yield
- Not available
- Beta
- 1.53
Profile
Company facts
- Exchange
- OTCMKTS
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US6085501095
- Market cap
- 658
- P/E ratio
- Not available
- Analyst target
- 18
- Dividend yield
- Not available
- Beta
- 1.53
About
About Molecular Templates Inc
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas. On April 20, 2025, Molecular Templates, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MTEM discussion.
5 years, 4 months ago
Molecular Templates, Inc is currently in a long term downtrend where the price is trading 22.4% below its 200 day moving average.
From a valuation standpoint, the stock is 98.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 24.0.
Molecular Templates, Inc's total revenue sank by 43.6% to $3M since the same quarter in the previous year.
Its net income has increased by 101.1% to $181K since the same quarter in the previous year.
Finally, its free cash flow fell by 327.7% to $-24M since the same quarter in the previous year.
Based on the above factors, Molecular Templates, Inc gets an overall score of 2/5.